Core Viewpoint - The company is actively participating in global pharmaceutical industry events and is closely monitoring cutting-edge technology developments and industry trends, including brain-computer interfaces [2] Group 1: Company Initiatives - The company is advancing its innovative flu drug, Yilikan, with hospital access work proceeding as planned [2] - The company is actively collaborating with local channels and medical institutions to expedite the drug's entry into hospitals, ensuring rapid access for patients [2] Group 2: Strategic Focus - The company is conducting careful research and planning for technological developments in line with its strategic growth needs, with commitments to timely information disclosure on any substantial progress [2]

Core Viewpoint - The core principle of Yilikan's pricing is to balance the innovative value of the drug with patient accessibility, aiming to offer more affordable prices for flu patients [1] Pricing Strategy - The company emphasizes a patient-centered approach, planning to use reasonable pricing and channel expansion to benefit a larger population [1] - If the company participates in medical insurance negotiations, any price adjustments will strictly follow negotiation rules, considering policy requirements, market conditions, and patient needs [1] Policy Engagement - The company is actively monitoring policy developments and preparing for potential negotiations related to medical insurance [1]

证券日报网讯1月6日，健康元（600380）在互动平台回答投资者提问时表示，壹立康作为抗流感1类创 新药，核心优势在于采用新型作用机制，能从源头阻断流感病毒复制，对甲型、乙型流感均有广谱抑制 效果，且全疗程仅需单次口服，用药便捷性和依从性大幅提升，安全性也经临床验证表现良好。目前该 产品已在京东健康、阿里健康等线上平台开放购买，可通过对应平台搜索"壹立康"便捷咨询下单。线下 方面，公司正有序推进全国主要城市药房及医院的开发工作，后续也将持续拓展销售渠道、推进市场开 发，让药品更易触达广大患者。 ...

（文章来源：证券日报） 证券日报网讯 1月6日，健康元在互动平台回答投资者提问时表示，公司始终严格遵守信息披露相关法 律法规，目前不存在应披露而未披露的重大信息，二级市场股价波动受宏观经济环境、行业政策导向、 市场情绪、资金流向等多重因素综合影响；流感药壹立康已于12月底在阿里健康、京东健康等平台上线 销售，终端定价综合考量了市场竞争格局、产品定位及相关政策要求，后续商业化推广工作正有序推 进；公司估值是市场各方基于行业发展前景、公司核心竞争力、经营基本面等多重因素形成的综合判 断，公司始终聚焦主业，持续推进创新转型，以扎实的研发成果和经营业绩为投资者创造长期价值；股 份回购事项需结合公司经营状况、资金安排及发展战略等综合考量，后续若有相关计划，公司将严格按 照监管规定履行审议程序及信息披露义务。 ...